A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.
Also called NCT01347710
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 795 participants
- Sponsor
- Lantheus Medical Imaging
- Registry
-
NCT01347710
-
- Other papers using this trial's data
- Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease
- Utility of 18F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Finland, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01347710. Allocation not applicable; no masking; primary purpose diagnostic. Start 2011-06 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2016-04-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Flurpiridaz F18
- Intervention (Drug)
- 99mTechnicium (sestamibi or tetrofosmin)
- Lead sponsor
- Lantheus Medical Imaging
Record details
- Record id
cardio:ct-nct01347710- Content hash
eff117d7b51bc840dc220baec3cda35a76841438edb27ea44c509a8a8eee68e1